The implementation of glucagon-like peptide 1 receptor agonist (GLP-1RA) medications has increased significantly over the past few years due to demonstrated efficacy with both weight loss and improvement in outcomes related to type 2 diabetes mellitus (T2DM). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.